Market capitalization | $589.90m |
Enterprise Value | $482.79m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 75.44 |
P/S ratio (TTM) P/S ratio | 92.17 |
P/B ratio (TTM) P/B ratio | 7.45 |
Revenue growth (TTM) Revenue growth | -50.69% |
Revenue (TTM) Revenue | $6.40m |
As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.
4 Analysts have issued a Arbutus Biopharma Corporation forecast:
4 Analysts have issued a Arbutus Biopharma Corporation forecast:
Mar '25 |
+/-
%
|
||
Revenue | 6.40 6.40 |
51%
51%
|
|
Gross Profit | 5.05 5.05 |
56%
56%
|
|
EBITDA | -62 -62 |
21%
21%
|
EBIT (Operating Income) EBIT | -64 -64 |
20%
20%
|
Net Profit | -77 -77 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.
Head office | Canada |
CEO | Lindsay Androski |
Employees | 44 |
Founded | 2005 |
Website | www.arbutusbio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.